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Abstract 
Background: Sensitive-relapsed small-cell lung cancer (SCLC) is thought to be sensitive to 
chemotherapy; therefore, second-line chemotherapy is recommended. Although platinum re-
challenge is performed in the second-line chemotherapy for sensitive-relapsed SCLC, it re-
mains unclear whether such a strategy is effective. Methods: We retrospectively analyzed the 
outcome of rechallenge chemotherapy for sensitive-relapsed SCLC. The endpoints of this study 
were progression-free survival from the time of relapse (PFS-Re) and overall survival from the 
time of relapse (OS-Re). We also compared the toxicity profile of rechallenge chemotherapy 
to that of first-line chemotherapy. Results: Of the 133 SCLC patients who received first-line 
treatment, 20 patients satisfied the definition of sensitive relapse and received rechallenge 
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chemotherapy. Combined carboplatin and etoposide was the most commonly used rechal-
lenge regimen, and 17 (85%) received it at a reduced dose due to hematological toxicity during 
the first-line treatment. Median PFS-Re and OS-Re were 4.5 months (95% CI: 3.5–5.4) and 10.5 
months (95% CI: 7.9–13.0), respectively. There was no association between dose adjustment 
and survival. The frequency of hematologic toxicity tended to be lower with rechallenge than 
first-line treatment. The incidence of grade 3 febrile neutropenia decreased from 40% in first-
line treatment to 15% in rechallenge. Conclusion: Platinum rechallenge could be a useful sec-
ond-line option for sensitive-relapsed SCLC, having favorable efficacy and safety. Dose adjust-
ment at rechallenge based on the toxicity profile during the first-line chemotherapy could re-
duce toxicity without weakening efficacy. © 2018 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Lung cancer is the leading cause of cancer-related death worldwide. Small-cell lung can-
cer (SCLC) accounts for approximately 13% of all lung cancer cases [1]. Although SCLC shows 
high sensitivity to first-line chemotherapy and radiotherapy, most patients develop disease 
relapse or progression [2]. The prognosis of relapsed SCLC patients is only 2–4 months with-
out second-line chemotherapy. 
Two major factors for predicting the efficacy of second-line chemotherapy in relapsed 
SCLC patients have been reported: (1) the response to first-line chemotherapy and (2) the 
relapse/progression-free interval [3–5]. According to these factors, relapsed SCLC can be di-
vided into two main groups: sensitive and refractory relapse. Patients who achieve a complete 
or partial response to the initial chemotherapy and relapsed more than 90 days after the last 
exposure to first-line chemotherapy are categorized as sensitive relapse, whereas those who 
failed to respond to the first-line chemotherapy or developed recurrence within 90 days after 
the last exposure to first-line chemotherapy are categorized as refractory relapse. While sen-
sitive relapse is thought to be responsive to further chemotherapy, second-line chemotherapy 
is recommended if the patient remains in good physical condition. 
The second-line treatment options for SCLC are limited. Topotecan is the only approved 
drug for second-line treatment for relapsed SCLC in the USA and EU. Single-agent oral topo-
tecan has shown to prolong overall survival (OS) and improve the quality of life, as compared 
with the best supportive care (median OS: 25.9 vs. 13.9 weeks; hazard ratio [HR] = 0.69; 95% 
confidence interval [CI]: 0.45–0.90; p = 0.01) [6]. In addition, the results of a past randomized 
study demonstrated that topotecan had similar efficacy to that of combined chemotherapy 
with cyclophosphamide plus doxorubicin plus vincristine, and improved control of several 
symptoms [7]. Therefore, topotecan is regarded as the standard second-line regimen for pa-
tients with sensitive-relapsed SCLC.  
Second-line chemotherapy using the same regimen as the first-line chemotherapy, so-
called “rechallenge chemotherapy,” is occasionally performed in clinical practice for patients 
with sensitive-relapsed SCLC. However, there are only a few studies about the efficacy of plat-
inum rechallenge chemotherapy. A retrospective analysis (n = 112) showed that the median 
OS from the initial diagnosis and that from rechallenge chemotherapy were 21.4 and 7.9 
months, respectively [8]. They described that rechallenge chemotherapy with platinum and 
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etoposide is a reasonable option that can potentially achieve better outcomes than standard 
monotherapy. Another report of second-line chemotherapy of SCLC showed that rechallenge 
chemotherapy (n = 30) was associated with better results for tumor response and OS, as com-
pared with other single agents, including topotecan (response rate: 35 vs. 18%, p = 0.06; me-
dian OS: 9.2 vs. 5.8 months, p = 0.08) [9]. In contrast, Wakuda et al. [10] found no significant 
difference in OS between rechallenge chemotherapy (n = 19) and monotherapy including am-
rubicin (n = 46) (14.4 vs. 13.3 months, HR = 0.89, 95% CI: 0.63–1.22; p = 0.51). Thus, whether 
rechallenge chemotherapy using the first-line regimen is effective remains unclear due to a 
lack of evidence. Moreover, the safety profile of rechallenge chemotherapy was not well doc-
umented in either report. 
In the current study, we retrospectively evaluated the clinical efficacy and safety of sec-
ond-line rechallenge chemotherapy for sensitive-relapsed SCLC. 
Patients and Methods 
We defined sensitive relapse according to previous reports: (1) an objective response to 
first-line chemotherapy or chemoradiotherapy and (2) relapse or progression more than 90 
days after the last exposure to first-line chemotherapy [3–5]. 
We screened clinical data from the medical records of patients with SCLC treated at the 
University of Tsukuba Hospital (Tsukuba, Japan) between January 2000 and December 2016. 
The collected clinical data included demographic characteristics, performance status at the 
time of relapse, disease stage at diagnosis (limited disease and extended disease), first-line 
regimen, response to first-line and rechallenge chemotherapies, type and dose of platinum 
regimen at rechallenge chemotherapy, and toxicity of both first-line and rechallenge chemo-
therapies.  
Computed tomography scans of the chest and abdomen and magnetic resonance imaging 
of the head were used to evaluate tumors according to the Response Evaluation Criteria in 
Solid Tumors (RECIST version 1.0.10). Patients without a radiological assessment were con-
sidered unevaluable and were excluded from this study. The objective response rate (ORR) 
was defined as the proportion of patients achieving either a complete response (CR) or a par-
tial response (PR). The disease control rate (DCR) was defined as the proportion of patients 
achieving CR, PR, and stable disease. 
Platinum regimen toxicities of both first-line and rechallenge chemotherapy were evalu-
ated by reviewing the medical records. All toxicities were graded according to the National 
Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 4.0). The 
study protocol was approved by the Institutional Review Board of the University of Tsukuba 
Hospital. 
The endpoints of this study were survival and the incidence of toxicity. Progression-free 
survival from relapse (PFS-Re) was defined as the interval from the initiation of rechallenge 
chemotherapy to disease progression or death from any cause. Similarly, overall survival from 
relapse (OS-Re) was defined as the interval from the initiation of rechallenge chemotherapy 
to death from any cause. Clinical evaluations of PFS-Re and OS-Re were conducted using the 
Kaplan-Meier method. Statistical analyses were performed using IBM SPSS statistics (version 
24.0) for Windows (IBM Corp., Armonk, NY, USA). 
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Results 
Patient Characteristics 
Figure 1 shows the flow diagram of the current study. Clinical data were collected from 
133 SCLC patients who received first-line chemotherapy or chemoradiotherapy. Ninety-one 
patients were confirmed to have disease progression or relapse after first-line treatment in 
our institute. Thirty-nine and 52 patients were categorized as having sensitive relapse and 
refractory relapse, respectively. In the sensitive-relapsed group, 28 patients received second-
line chemotherapy. Among the sensitive-relapsed SCLC patients who received second-line 
chemotherapy, 20 received platinum rechallenge and the remainder received amrubicin mon-
otherapy. 
The characteristics of patients who received rechallenge chemotherapy are summarized 
in Table 1. The median age was 65 years (range 52–84), and 85% were males. Eleven patients 
presented at diagnosis with limited disease, and the other 9 presented with extended disease. 
The most common first-line regimen was combined carboplatin and etoposide (CBDCA/ETP; 
14/20, 70%). The median relapse/progression-free interval was 115 days (range 91–404). 
Rechallenge Dose 
Among the patients who received rechallenge chemotherapy, 17 (85%) patients started 
a reduced-dose second-line chemotherapy because of severe adverse events during first-line 
treatment. In all, 13 patients received an 80% dose, one received a 75% dose, and the other 3 
received a 70% dose. Only 3 patients could start the second-line rechallenge chemotherapy at 
full dose. 
Toxicity 
Table 2 shows treatment-related adverse events associated with the first-line and rechal-
lenge chemotherapy. Grade 3 or worse hematological toxicity was noted in both groups. How-
ever, it appeared to be less frequent in rechallenge chemotherapy. The incidence of febrile 
neutropenia tended to be higher in the first-line than in the rechallenge chemotherapy (grade 
3: 8 [40%] first-line vs. 3 [15%] rechallenge). Nonhematologic toxicity was relatively mild in 
both groups. No treatment-related death occurred in either group. 
Efficacy 
The median number of cycles with rechallenge chemotherapy was 3 (range 1–4). The re-
sponse to rechallenge chemotherapy was CR of 0%, PR of 50% (10/20), stable disease of 30% 
(6/20), and progressive disease of 20% (4/20), with ORR of 50% and DCR of 80%. In amru-
bicin-treated patients, the ORR was 25% and DCR was 88%. 
In the patients treated with rechallenge chemotherapy, the median PFS-Re and OS-Re 
were 4.5 months (95% CI: 3.5–5.4; Fig. 2a) and 10.5 months (95% CI: 7.9–13.0; Fig. 2b), re-
spectively. We further evaluated whether dose adjustment at rechallenge chemotherapy af-
fected the PSF-Re and OS-Re. Figure 3 presents the correlation between PFS-Re and rechal-
lenge chemotherapy dose; dose reduction of rechallenge chemotherapy did not affect PFS-Re. 
Similarly, dose reduction did not affect OS-Re (data not shown). 
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Subsequent Therapy 
Among the patients who received rechallenge chemotherapy, 12 (60%) received third-
line chemotherapy. The remaining 8 patients did not receive third-line chemotherapy because 
they were transferred to the palliative care unit, refused further chemotherapy, or died. 
Among the patients who received third-line chemotherapy, 11 received amrubicin, and the 
other patient received topotecan. 
Discussion 
Rechallenge with a first-line platinum regimen has been performed in clinical practice for 
patients with sensitive-relapsed SCLC without clear evidence that rechallenge chemotherapy 
is useful for them. The results of this study showed that rechallenge chemotherapy had a fa-
vorable efficacy and safety profile. 
We showed that most patients received rechallenge chemotherapy safely by optimal dose 
adjustment. A combination of CBDCA and ETP was the most commonly used platinum regi-
men as the first-line treatment, and 17 of 20 (85%) patients experienced hematologic toxicity 
of grade 3 or higher. We then selected the patients who needed dose adjustment of rechallenge 
chemotherapy based on the toxicity profiles during the first-line treatment. As a result, the 
incidence of hematologic toxicity decreased compared to that in first-line therapy, especially, 
the frequency of grade 3 febrile neutropenia from 40 to 15%. Neither treatment failure due to 
toxicity nor treatment-related death was observed. Thus, we could reduce the toxicity at re-
challenge chemotherapy adequately because we referred to a toxicity profile of the first-line 
chemotherapy. We consider that the optimal dose adjustment for reasonable toxicity profile 
is an important advantage of rechallenge chemotherapy, because candidates for the second-
line chemotherapy are heavily treated previously, and therefore severe hematological toxicity 
is anticipated. 
In the current study, rechallenge chemotherapy showed a favorable efficacy; median PFS-
Re and OS-Re were 4.5 and 10.5 months, respectively. Moreover, PFS-Re and OS-Re were not 
associated with dose adjustment of rechallenge chemotherapy. Previous studies showed that 
median PFS and OS from relapse were 5.5 and 7.9–14.4 months, respectively [8–11]. Although 
these outcomes were comparable to those of the current study, the association between sur-
vival and dose intensity has not been documented in either report. A recent randomized phase 
3 trial compared the efficacy of combined therapy with cisplatin, etoposide, and irinotecan 
(PEI) to topotecan monotherapy in patients with sensitive-relapsed SCLC [12]. In this study, 
PEI consisted of alternating weeks of the two platinum combinations, cisplatin plus etoposide 
(PE) and cisplatin plus irinotecan (PI). PEI can be regarded as combined therapy with two 
platinum rechallenges because both PI and PE were used as first-line regimen. Although many 
patients who received PEI required a dose reduction due to severe hematological toxicity, PEI 
showed better OS than the topotecan group (18.2 vs. 12.5 months; HR = 0.67, 95% CI: 0.51–
0.88; p = 0.0079). Since sensitive-relapsed SCLC remained sensitive to first-line platinum reg-
imen, rechallenge chemotherapy showed favorable efficacy even though the patients received 
it at a reduced dose. 
There were several limitations in this study. First, the current study was a single-institu-
tion, retrospective study with a relatively small sample size. Therefore, we consider that this 
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study is a hypothesis-generating study for future investigations. Second, an optimal compar-
ator for the rechallenge chemotherapy group was lacking because there were only a few pa-
tients who received monotherapy. All patients received amrubicin as the second-line mono-
therapy. Amrubicin, a fully synthetic 9-aminoanthracycline, is widely used for the second-line 
treatment of SCLC in Japan. Several studies reported that the efficacy of amrubicin as a second-
line treatment for SCLC was promising, with an ORR of 31–52% and median PFS of 3.5–4.2 
months [13–15]. Amrubicin could be a reasonable comparator if the randomized phase III trial 
to evaluate the efficacy of rechallenge chemotherapy is performed in the future. 
In conclusion, the results of the current study showed that rechallenge chemotherapy 
could be a useful second-line option for sensitive-relapsed SCLC, with favorable efficacy and 
safety. Optimal dose adjustment of rechallenge chemotherapy is an important treatment strat-
egy to reduce toxicity without adversely affecting survival. 
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Fig. 1. CONSORT flow diagram of the current study. 
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Fig. 2. Kaplan-Meier curves of PFS-Re (a) and OS-Re (b) for patients receiving second-line platinum rechal-
lenge (n = 20). 
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Fig. 3. Swimmer plots for patients receiving rechallenge chemotherapy. Bar length indicates PFS-Re for 
each patient. Patients receiving rechallenge chemotherapy at full dose are presented in gray, whereas 
those receiving rechallenge chemotherapy at an 80% and less than 80% are presented in dark gray and 
black, respectively. 
 
 
 
 
Table 1. Patient characteristics in the platinum rechallenge group (n = 20) 
  
  
Age, years 065 (52–84) 
Gender  
Male/Female 017/3 
Performance status at the relapse  
0 007 
1 011 
2 000 
3 002 
Disease extent at the initial diagnosis  
Limited disease 011 
Extended disease 009 
First-line therapy  
Chemoradiotherapy 009 
Chemotherapy 011 
First-line regimen  
Carboplatin and etoposide 014 
Cisplatin and etoposide 005 
Cisplatin and irinotecan 001 
Recurrence-free intervals, (days 115 (91–404) 
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Table 2. Adverse event at first-line and rechallenge treatment 
          
          
Grade First-line, %  Rechallenge, % 
     2 3 4 03+4  2 3 4 03+4 
          
          
Hematological          
Leukopenia 2 8 8 80  4 8 7 75 
Neutropenia 1 6 11 85  1 9 4 65 
Anemia 2 1 0 05  1 0 0 00 
Thrombocytopenia 2 3 2 25  3 2 0 10 
Febrile neutropenia 0 8 0 40  0 3 0 15 
Nonhematological          
Anorexia 3 3 0 15  4 0 0 00 
Nausea/vomit 3 1 0 05  2 0 0 00 
Diarrhea 1 0 0 00  0 0 0 00 
Fatigue 3 0 0 00  2 0 0 00 
Edema 1 0 0 00  1 0 0 00 
Increased AST/ALT 1 0 0 00  0 0 0 00 
Increased creatinine 2 1 0 05  1 0 0 00 
          
          
 
 
 
